Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.

Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders. Abstract Text:

Charles B Nemeroff,

A large and growing literature suggests that traumatic experiences early in life increase the risk of mood and anxiety disorders in genetically predisposed persons. Findings from laboratory animal studies as well as studies of women with histories of early-life trauma demonstrate that long-lived alterations in the corticotropin-releasing factor (CRF) system and stress responses underlie this vulnerability.Women with histories of abuse plus current depression exhibit the greatest abnormalities in the hypothalamicpituitary response to stress and may represent a unique cohort of patients. Studies in laboratory animals also suggest that persistent changes in the CRF system may be reversed by antidepressants or surrogate parenting, which underscores the urgent need for primary and secondary prevention studies in children who are living in adverse or dangerous environments.

Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders. Publishing Authors By Initials

CB Nemeroff,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Psychopharmacology bulletin

VOLUME: 38 Suppl 1

Page Numbers: 14-20

Journal Abbreviation:

ISSN: 0048-5764

DAY: 26

MONTH: 10

YEAR: 2004

Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101123

Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.

AFFILIATION: Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine in Atlanta, GA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Psychopharmacol Bull

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders Related Publications

• An interactive web-based method of outreach to college students at risk for suicide.
• CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
• Cuba II: A Land Stuck in Time.
• Cuba: a land stuck in time.
• Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.
• Depression and endocrine disorders: focus on the thyroid and adrenal system.
• Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University.
• Drug development for anxiety disorders: new roles for atypical antipsychotics.
• Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.
• Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.
• Emerging treatments for depression.
• Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.
• Fostering foster care outcomes: quality of intervention matters in overcoming early adversity.
• How are you?
• Involvement of neuropeptide systems in schizophrenia: human studies.
• Neuropeptides and Alzheimer's disease.
• Neurotensin: role in psychiatric and neurological diseases.
• New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
• One brain, but different clinical disciplines: should psychiatry and neurology be United?
• Overview of the safety of citalopram.
• Sertraline and desmethylsertraline in human breast milk and nursing infants.
• Stress, menopause and vulnerability for psychiatric illness.
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.
• The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.
• The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.
• The neurobiology of bipolar disorder.
• The neurobiology of social anxiety disorder: the relevance of fear and anxiety.
• The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations.
• The role of patient advocacy in funding policy.
• Understanding the pathophysiology of postpartum depression: implications for the development of novel treatments.